Cargando…

Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice

We developed a novel platform to express high levels of recombinant lipoproteins with intrinsic adjuvant properties. Based on this technology, our group developed recombinant lipidated dengue envelope protein domain IIIs as vaccine candidates against dengue virus. This work aims to evaluate the immu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiang, Chen-Yi, Pan, Chien-Hsiung, Chen, Mei-Yu, Hsieh, Chun-Hsiang, Tsai, Jy-Ping, Liu, Hsueh-Hung, Liu, Shih-Jen, Chong, Pele, Leng, Chih-Hsiang, Chen, Hsin-Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965760/ https://www.ncbi.nlm.nih.gov/pubmed/27470096 http://dx.doi.org/10.1038/srep30648

Ejemplares similares

Lipidated Dengue-2 Envelope Protein Domain III Independently Stimulates Long-Lasting Neutralizing Antibodies and Reduces the Risk of Antibody-Dependent Enhancement
por: Chiang, Chen-Yi, et al.
Publicado: (2013)

The Immunodominance Change and Protection of CD4(+) T-Cell Responses Elicited by an Envelope Protein Domain III-Based Tetravalent Dengue Vaccine in Mice
por: Chen, Hsin-Wei, et al.
Publicado: (2015)

Dengue-1 Envelope Protein Domain III along with PELC and CpG Oligodeoxynucleotides Synergistically Enhances Immune Responses
por: Chiang, Chen-Yi, et al.
Publicado: (2012)

A Novel Single-Dose Dengue Subunit Vaccine Induces Memory Immune Responses
por: Chiang, Chen-Yi, et al.
Publicado: (2011)

Immunogenicity of a novel tetravalent dengue envelope protein domain III-based antigen in mice
por: Fahimi, Hossein, et al.
Publicado: (2018)

A Purified Recombinant Lipopeptide as Adjuvant for Cancer Immunotherapy
por: Song, Ying-Chyi, et al.
Publicado: (2014)

Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
por: Biswal, Shibadas, et al.
Publicado: (2021)

Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity
por: Mintaev, Ramil R., et al.
Publicado: (2023)

Immunogenicity and Safety of a Recombinant Tetravalent Dengue Vaccine in Children and Adolescents Ages 9–16 Years in Brazil
por: Dayan, Gustavo H., et al.
Publicado: (2013)

Neutralizing Antibody Response and Efficacy of Novel Recombinant Tetravalent Dengue DNA Vaccine Comprising Envelope Domain III in Mice
por: Kulkarni, Ajit, et al.
Publicado: (2017)

Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico
por: Dayan, Gustavo H, et al.
Publicado: (2014)

Tetravalent dengue DNA vaccine is not immunogenic when delivered by retrograde infusion into salivary glands
por: El Helou, Guy, et al.
Publicado: (2020)

Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial
por: Turner, Mark, et al.
Publicado: (2020)

Virus-like particles with FLAG-tagged envelope protein as a tetravalent dengue vaccine candidate
por: Imagawa, Toshifumi, et al.
Publicado: (2021)

Recombinant lipoprotein-based vaccine candidates against C. difficile infections
por: Huang, Jui-Hsin, et al.
Publicado: (2015)

Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties
por: Liu, Yan, et al.
Publicado: (2014)

Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination
por: Vigne, Claire, et al.
Publicado: (2017)

Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults
por: LeFevre, Inge, et al.
Publicado: (2023)

Efficient Uptake of Recombinant Lipidated Survivin by Antigen-Presenting Cells Initiates Antigen Cross-Presentation and Antitumor Immunity
por: Chiang, Chen-Yi, et al.
Publicado: (2018)

Immunodomination of Serotype-Specific CD4+ T-Cell Epitopes Contributed to the Biased Immune Responses Induced by a Tetravalent Measles-Vectored Dengue Vaccine
por: Lin, Tsung-Han, et al.
Publicado: (2020)

Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines
por: Hou, Jue, et al.
Publicado: (2022)

Degradable emulsion as vaccine adjuvant reshapes antigen-specific immunity and thereby ameliorates vaccine efficacy
por: Huang, Chung-Hsiung, et al.
Publicado: (2016)

Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 years: Phase II randomized controlled trial in Singapore
por: Sin Leo, Yee, et al.
Publicado: (2012)

Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2–17 years: systematic review and meta-analysis
por: Rosa, Bruno Rodrigues, et al.
Publicado: (2019)

Detection and quantification of dengue virus using a novel biosensor system based on dengue NS3 protease activity
por: Hsieh, Ming-Shu, et al.
Publicado: (2017)

Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue
por: Sáez-Llorens, Xavier, et al.
Publicado: (2023)

Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults
por: Kirstein, Judith, et al.
Publicado: (2018)

Identification of synthetic vaccine candidates against SARS CoV infection
por: Lien, Shu-Pei, et al.
Publicado: (2007)

Immunogenicity Studies of Bivalent Inactivated Virions of EV71/CVA16 Formulated with Submicron Emulsion Systems
por: Lin, Chih-Wei, et al.
Publicado: (2014)

Production of tetravalent dengue virus envelope protein domain III based antigens in lettuce chloroplasts and immunologic analysis for future oral vaccine development
por: van Eerde, André, et al.
Publicado: (2019)

A tetravalent dengue nanoparticle stimulates antibody production in mice
por: Silva, Elisângela F, et al.
Publicado: (2012)

Recombinant Lipidated HPV E7 Induces a Th-1-Biased Immune Response and Protective Immunity against Cervical Cancer in a Mouse Model
por: Huang, Chiung-Yi, et al.
Publicado: (2012)

Recombinant lipidated Zika virus envelope protein domain III elicits durable neutralizing antibody responses against Zika virus in mice
por: Chen, Mei-Yu, et al.
Publicado: (2020)

Evaluation of envelope domain III-based single chimeric tetravalent antigen and monovalent antigen mixtures for the detection of anti-dengue antibodies in human sera
por: Batra, Gaurav, et al.
Publicado: (2011)

Vaccination With a Single Consensus Envelope Protein Ectodomain Sequence Administered in a Heterologous Regimen Induces Tetravalent Immune Responses and Protection Against Dengue Viruses in Mice
por: Wang, Ran, et al.
Publicado: (2019)

Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions
por: Moris, Philippe, et al.
Publicado: (2019)

Simulations to compare efficacies of tetravalent dengue vaccines and mosquito vector control
por: THAVARA, U., et al.
Publicado: (2014)

Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines
por: Russell, Philip K., et al.
Publicado: (2016)

Design of Monovalent and Chimeric Tetravalent Dengue Vaccine Using an Immunoinformatics Approach
por: Dixit, Neeraj Kumar
Publicado: (2021)

Efficacy of Tetravalent Dengue Vaccine: A Systematic Review and Meta-Analysis
por: Khobragade, Ashish Wasudeo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3273e6dnmfkm4cr8hgpue0itfp